Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01212588 · ClinicalTrials.gov registry record · Phase 2
Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)
A Phase 2 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01212588 is a Phase 2 study that was terminated before completion, run by Indiana University. The registered enrollment target is 22 participants.
The verdict
NCT01212588, a Phase 2 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
Participants will be randomized to either Mifepristone 600mg once daily for seven days or Placebo tablet once daily for seven days. Rating scales, vital signs, cortisol levels will be collected for evaluation.
Interventions
- DRUG Placebo
- DRUG mifepristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-09 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01212588
The ClinicalTrials.gov registry entry for NCT01212588 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01212588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01212588 about?
NCT01212588 is a clinical study titled "Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)". Participants will be randomized to either Mifepristone 600mg once daily for seven days or Placebo tablet once daily for seven days. Rating scales, vital signs, cortisol levels will be collected for evaluation.
What is the current status of trial NCT01212588?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2010-09. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01212588?
The interventions under investigation include: Placebo (DRUG), mifepristone (DRUG).
Who is sponsoring clinical trial NCT01212588?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.